These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 30451936)

  • 1. Recent trends in mucopolysaccharidosis research.
    Kobayashi H
    J Hum Genet; 2019 Feb; 64(2):127-137. PubMed ID: 30451936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of brain disease in the mucopolysaccharidoses.
    Scarpa M; Orchard PJ; Schulz A; Dickson PI; Haskins ME; Escolar ML; Giugliani R
    Mol Genet Metab; 2017 Dec; 122S():25-34. PubMed ID: 29153844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and potential therapeutic strategies for mucopolysaccharidoses.
    Noh H; Lee JI
    J Clin Pharm Ther; 2014 Jun; 39(3):215-24. PubMed ID: 24612142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adeno-associated viral gene therapy for mucopolysaccharidoses exhibiting neurodegeneration.
    Lau AA; Hemsley KM
    J Mol Med (Berl); 2017 Oct; 95(10):1043-1052. PubMed ID: 28660346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucopolysaccharidosis and Autophagy: Controversies on the Contribution of the Process to the Pathogenesis and Possible Therapeutic Applications.
    Pierzynowska K; Gaffke L; Podlacha M; Brokowska J; Węgrzyn G
    Neuromolecular Med; 2020 Mar; 22(1):25-30. PubMed ID: 31372809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Principles of therapeutic approaches for mucopolysaccharidoses].
    Caillaud C
    Arch Pediatr; 2014 Jun; 21 Suppl 1():S39-45. PubMed ID: 25063383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of the mucopolysaccharidoses.
    Muenzer J
    Rheumatology (Oxford); 2011 Dec; 50 Suppl 5():v4-12. PubMed ID: 22210669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New treatments for the mucopolysaccharidoses: from pathophysiology to therapy.
    Fecarotta S; Gasperini S; Parenti G
    Ital J Pediatr; 2018 Nov; 44(Suppl 2):124. PubMed ID: 30442204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mucopolysaccharidoses--biochemical mechanisms of diseases and therapeutic possibilities].
    Kloska A; Tylki-Szymańska A; Wegrzyn G
    Postepy Biochem; 2011; 57(2):133-47. PubMed ID: 21913414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucopolysaccharidosis type III (Sanfilippo Syndrome): emerging treatment strategies.
    de Ruijter J; Valstar MJ; Wijburg FA
    Curr Pharm Biotechnol; 2011 Jun; 12(6):923-30. PubMed ID: 21235449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxidative Stress in Mucopolysaccharidoses: Pharmacological Implications.
    Pierzynowska K; Gaffke L; Cyske Z; Węgrzyn G; Buttari B; Profumo E; Saso L
    Molecules; 2021 Sep; 26(18):. PubMed ID: 34577086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene therapy for Mucopolysaccharidoses.
    Sawamoto K; Chen HH; Alméciga-Díaz CJ; Mason RW; Tomatsu S
    Mol Genet Metab; 2018 Feb; 123(2):59-68. PubMed ID: 29295764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.
    Garcia-Rivera MF; Colvin-Wanshura LE; Nelson MS; Nan Z; Khan SA; Rogers TB; Maitra I; Low WC; Gupta P
    Brain Res Bull; 2007 Nov; 74(6):429-38. PubMed ID: 17920451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical review of current MPS guidelines and management.
    Stapleton M; Hoshina H; Sawamoto K; Kubaski F; Mason RW; Mackenzie WG; Theroux M; Kobayashi H; Yamaguchi S; Suzuki Y; Fukao T; Tadao O; Ida H; Tomatsu S
    Mol Genet Metab; 2019 Mar; 126(3):238-245. PubMed ID: 30143438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.
    Sato Y; Okuyama T
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy for neurologic manifestations of mucopolysaccharidoses.
    Wolf DA; Banerjee S; Hackett PB; Whitley CB; McIvor RS; Low WC
    Expert Opin Drug Deliv; 2015 Feb; 12(2):283-96. PubMed ID: 25510418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses.
    Banecka-Majkutewicz Z; Jakóbkiewicz-Banecka J; Gabig-Cimińska M; Węgrzyn A; Węgrzyn G
    Arch Immunol Ther Exp (Warsz); 2012 Dec; 60(6):461-8. PubMed ID: 22949095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Has resveratrol a potential for mucopolysaccharidosis treatment?
    Rintz E; Pierzynowska K; Podlacha M; Węgrzyn G
    Eur J Pharmacol; 2020 Dec; 888():173534. PubMed ID: 32877657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Emerging Therapies for Mucopolysaccharidoses.
    Lagler FB
    Handb Exp Pharmacol; 2020; 261():39-56. PubMed ID: 31451968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mucopolysaccharidoses. New therapeutic possibilities increase the need of early diagnosis].
    Malm G; Bondeson ML; von Döbeln U; Månsson JE
    Lakartidningen; 2002 Apr; 99(16):1804-9. PubMed ID: 12043480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.